SCHEMBL3527430

SCHEMBL3527430

Nc1cc(F)ccc1NC1C[C@H]2CC[C@@H](C1)N2C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 7/20 0.43
CHEK1 O14757 1/20 0.40
NTRK1 P04629 1/20 0.40
MET P08581 1/20 0.40
PIM1 P11309 1/20 0.40
LTK P29376 1/20 0.40
GRK5 P34947 1/20 0.40
MAP2K2 P36507 1/20 0.40
CDK8 P49336 1/20 0.40
NEK2 P51955 1/20 0.40
LIMK1 P53667 1/20 0.40
TYRO3 Q06418 1/20 0.40
MAP4K2 Q12851 1/20 0.40
DYRK1A Q13627 1/20 0.40
AURKB Q96GD4 1/20 0.40
ALOX15 P16050 2/20 0.39
HDAC2 Q92769 5/20 0.39
HDAC3 O15379 7/20 0.38
NCOR2 Q9Y618 4/20 0.38
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13543529 0.83 GPR119 (0.50) HDAC1HDAC2CHRM2CHRM1CHRM3
SCHEMBL7226906 0.81 GAA (0.50) HDAC1HDAC2HDAC3HDAC8CHRM1
SCHEMBL7237208 0.81 GAA (0.50) HDAC1HDAC2HDAC3HDAC8CHRM1
SCHEMBL4396685 0.81 GAA (0.50) HDAC1HDAC2HDAC3HDAC8CHRM1
SCHEMBL31196402 0.81 HDAC1 (0.49) HDAC1CHEK1NTRK1METPIM1
SCHEMBL3528128 0.81 GPR119 (0.44) CHEK1NTRK1METPIM1LTK
SCHEMBL3526469 0.81 HCAR3 (0.52) CCR3MEN1KMT2A
SCHEMBL3526475 0.81 HCAR3 (0.52) CCR3MEN1KMT2A
SCHEMBL5821200 0.77 MEN1 (0.38) MEN1KMT2ALTA4H
SCHEMBL6017233 0.77 MEN1 (0.54) CCR3MEN1KMT2ALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 HDAC1 1736/4885CHEK1 1023/4885NTRK1 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.